Provided by Tiger Fintech (Singapore) Pte. Ltd.

Karyopharm Therapeutics

7.36
+0.60008.88%
Post-market: 7.10-0.2600-3.53%18:53 EDT
Volume:120.30K
Turnover:896.97K
Market Cap:63.08M
PE:-0.53
High:7.90
Open:6.73
Low:6.73
Close:6.76
Loading ...

Karyopharm Therapeutics Inc expected to post a loss of $4.18 a share - Earnings Preview

Reuters
·
02 May

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
02 May

RBC Lowers Price Target on Karyopharm Therapeutics to $43 From $45, Keeps Outperform Rating

MT Newswires Live
·
03 Apr

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire
·
02 Apr

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks
·
01 Apr

Karyopharm Therapeutics (KPTI) Receives a Buy from Piper Sandler

TIPRANKS
·
19 Mar

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire
·
04 Mar

Karyopharm Therapeutics Is Maintained at Outperform by Baird

Dow Jones
·
03 Mar

Karyopharm Therapeutics Inc : Baird Cuts Target Price to $54 From $75

THOMSON REUTERS
·
28 Feb

Karyopharm Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
26 Feb

Karyopharm Therapeutics Inc : H.c. Wainwright Adjusts Target Price to $56 From $7 to Reflect 1-for-15 Reverse Stock Split

THOMSON REUTERS
·
26 Feb

Karyopharm trading halted, news pending

TIPRANKS
·
26 Feb

Karyopharm Therapeutics to Implement 1-for-15 Reverse Stock Split

MT Newswires Live
·
25 Feb

Karyopharm Announces 1-for-15 Reverse Stock Split

THOMSON REUTERS
·
24 Feb

Karyopharm Announces 1-for-15 Reverse Stock Split

PR Newswire
·
24 Feb

Karyopharm Therapeutics: Hold Rating Maintained Amid Revenue Stagnation and Competitive Pressures

TIPRANKS
·
23 Feb

Karyopharm Therapeutics Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Feb

Karyopharm Therapeutics: Strong Financial Performance and Strategic Developments Justify Buy Rating

TIPRANKS
·
20 Feb

Karyopharm Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
20 Feb

Barclays Sticks to Its Buy Rating for Karyopharm Therapeutics (KPTI)

TIPRANKS
·
20 Feb